Seattle Children’s Research Featured in Worldwide Study on COVID-19 Vaccine Safety in Young Children
Written by Casey Egan and Empress Rivera-Ruiz, On the Pulse, February 16, 2023.
New findings from Seattle Children’s Research Institute’s Center for Clinical and Translational Research reveal that a three-dose primary series of Pfizer’s COVID-19 vaccine was safe and effective in children 6 months to 4 years of age, even when a new variant (Omicron) was circulating.
The findings were released on Feb. 16 in the New England Journal of Medicine by an international team conducting the study, including Seattle Children’s lead study investigator, Dr. Janet Englund.
“No data on a three-dose series of Pfizer mRNA vaccine has been previously published in young children,” said Dr. Englund.
Dr. Englund also noted that the findings demonstrate that three doses of the Pfizer vaccine offer better protection than two doses against the Omicron variant in this age group.
Studies of bivalent booster doses of the Pfizer mRNA vaccine are now ongoing at Seattle Children’s. This research continues under Seattle Children’s Pediatric Infectious Disease Research Group, directed by Dr. Englund.
Learn more here: COVID-19 Vaccine Found Safe, Effective for Youngest Children (seattlechildrens.org)
Resources:
